Presentation is loading. Please wait.

Presentation is loading. Please wait.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Similar presentations


Presentation on theme: "Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC."— Presentation transcript:

1 Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC

2 Activity Goals

3 Patient Case Study

4 Patient History

5 CheckMate 017: Nivolumab vs Docetaxel in Refractory, Squamous, Advanced NSCLCa

6 CheckMate 017: Results in Squamous NSCLC

7 CheckMate 057: Nivolumab vs Docetaxel in Refractory, Advanced Non-squamous NSCLC

8 CheckMate 057: Results

9 Checkpoint Inhibitors Being Evaluated for the First-Line Treatment of NSCLC

10 First-line Treatment of NSCLC

11 PDL1: Challenges in Biomarker Development

12 CheckMate 057: OS Based on PD-L1 Expression

13 CheckMate 057: Response Rates

14 Current Status of PD-1 Inhibitors in Clinical Practice

15 Pembrolizumab in Patients With Brain Metastases: Phase 2 Study

16 Efficacy of Immunotherapy

17 Patient History (Follow-up)

18 Outstanding Issues

19 Immune-Mediated Adverse Events With PD-1 Inhibitors

20 Abbreviations

21 References

22 References (cont)

23 References (cont)

24 References (cont)

25 References (cont)

26 References (cont)

27 References (cont)


Download ppt "Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC."

Similar presentations


Ads by Google